Severe IL-6–dominant immune-mediated inflammatory response complicated by probable arginine vasopressin deficiency following ivonescimab-based therapy in advanced EGFR-mutant lung squamous cell carcinoma: a case report - Summary - MDSpire
Advertisement
Severe IL-6–dominant immune-mediated inflammatory response complicated by probable arginine vasopressin deficiency following ivonescimab-based therapy in advanced EGFR-mutant lung squamous cell carcinoma: a case report
To report a case of severe immune-related adverse events following ivonescimab treatment in a patient with advanced EGFR-mutant lung squamous cell carcinoma.
Key Findings:
The patient developed a severe IL-6–dominant inflammatory response after ivonescimab treatment.
Corticosteroids provided rapid relief from fever, indicating an IL-6–mediated process.
Re-exposure to ivonescimab resulted in a more severe reaction and symptoms consistent with arginine vasopressin deficiency.
Interpretation:
Limitations:
The case study is based on a single patient, limiting generalizability.
Causal relationships between treatment and adverse events cannot be definitively established.
